Immunotherapy-related adverse events (irAEs): extraction from FDA drug labels and comparative analysis

OBJECTIVES: Immune checkpoint inhibitors (ICIs) have dramatically improved outcomes in cancer patients. However, ICIs are associated with significant immune-related adverse events (irAEs) and the underlying biological mechanisms are not well-understood. To ensure safe cancer treatment, research effo...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, QuanQiu, Xu, Rong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Research and Applications
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6447026/
https://www.ncbi.nlm.nih.gov/pubmed/30976759
http://dx.doi.org/10.1093/jamiaopen/ooy045

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6447026/
https://www.ncbi.nlm.nih.gov/pubmed/30976759
http://dx.doi.org/10.1093/jamiaopen/ooy045

Ejemplares similares